Literature DB >> 25495587

Levels of C-reactive protein (CRP) in patients with schizophrenia, unipolar depression and bipolar disorder.

Adam Wysokiński1, Aleksandra Margulska, Dominik Strzelecki, Iwona Kłoszewska.   

Abstract

OBJECTIVE: C-reactive protein (CRP) is the major acute-phase plasma protein. Studies show that patients with various mental disorders have elevated levels of CRP. The aim of the study was to determine differences in CRP serum level in patients with acute schizophrenia, unipolar depression, bipolar depression and bipolar mania.
METHOD: Serum level of CRP was measured in 950 Caucasian inpatients (589 women, 62.0%; mean age 50.3 years).
RESULTS: Mean concentration of CRP in study groups was: schizophrenia (n = 485) 5.30 mg/l, unipolar depression (n = 319) 5.61 mg/l, bipolar disorder (n = 146) 4.65 mg/l, bipolar depression (n = 114) 3.82 mg/l and bipolar mania (n = 32) 7.36 mg/l. There was no difference for CRP levels between patients with schizophrenia, unipolar depression, bipolar depression and bipolar mania (P = 0.58). The overall rate of being above the high level of CRP (set at 3.0 mg/l) was 35.7% for schizophrenia, 38.6% for unipolar depression, 40.4% for bipolar disorder, 40.4% for bipolar depression and 40.6% for bipolar mania. There were no significant differences in the risk of having high level of CRP between the clinical groups. The rate of patients being above high level was higher in women. We also found that in whole study group CRP level was positively correlated with age (P = 0.002).
CONCLUSIONS: Although there is no statistically significant difference in CRP serum level between patients with schizophrenia, unipolar depression, bipolar depression and bipolar mania, our results show that more than one-third (37.4%) of all subjects had CRP level > 3 mg/l, which is the cut-off point for high cardiovascular risk.

Entities:  

Keywords:  Bipolar disorder; C-reactive protein; CRP; Depression; Mania; Schizophrenia

Mesh:

Substances:

Year:  2014        PMID: 25495587     DOI: 10.3109/08039488.2014.984755

Source DB:  PubMed          Journal:  Nord J Psychiatry        ISSN: 0803-9488            Impact factor:   2.202


  24 in total

Review 1.  Systemic Biomarkers of Accelerated Aging in Schizophrenia: A Critical Review and Future Directions.

Authors:  Tanya T Nguyen; Lisa T Eyler; Dilip V Jeste
Journal:  Schizophr Bull       Date:  2018-02-15       Impact factor: 9.306

2.  Hypovitaminosis D is associated with negative symptoms, suicide risk, agoraphobia, impaired functional remission, and antidepressant consumption in schizophrenia.

Authors:  G Fond; M Faugere; C Faget-Agius; M Cermolacce; R Richieri; L Boyer; C Lançon
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2018-08-04       Impact factor: 5.270

3.  Telomere attrition and inflammatory load in severe psychiatric disorders and in response to psychotropic medications.

Authors:  Alessio Squassina; Mirko Manchia; Claudia Pisanu; Raffaella Ardau; Carlo Arzedi; Alberto Bocchetta; Paola Caria; Cristina Cocco; Donatella Congiu; Eleonora Cossu; Tinuccia Dettori; Daniela Virginia Frau; Mario Garzilli; Elias Manca; Anna Meloni; Maria Antonietta Montis; Andrea Mura; Mariella Nieddu; Barbara Noli; Pasquale Paribello; Federica Pinna; Renato Robledo; Giovanni Severino; Valeria Sogos; Maria Del Zompo; Gian Luca Ferri; Caterina Chillotti; Roberta Vanni; Bernardo Carpiniello
Journal:  Neuropsychopharmacology       Date:  2020-09-12       Impact factor: 7.853

4.  Chronic Peripheral Inflammation is Associated With Cognitive Impairment in Schizophrenia: Results From the Multicentric FACE-SZ Dataset.

Authors:  Ewa Bulzacka; Laurent Boyer; Franck Schürhoff; Ophélia Godin; Fabrice Berna; Lore Brunel; Méja Andrianarisoa; Bruno Aouizerate; Delphine Capdevielle; Isabelle Chéreau-Boudet; Gabrielle Chesnoy-Servanin; Jean-Marie Danion; Caroline Dubertret; Julien Dubreucq; Catherine Faget; Franck Gabayet; Tifenn Le Gloahec; Pierre-Michel Llorca; Jasmina Mallet; David Misdrahi; Romain Rey; Raphaëlle Richieri; Christine Passerieux; Paul Roux; Hanan Yazbek; Marion Leboyer; Guillaume Fond
Journal:  Schizophr Bull       Date:  2016-05-03       Impact factor: 9.306

5.  Increased peripheral inflammation in schizophrenia is associated with worse cognitive performance and related cortical thickness reductions.

Authors:  Hayley F North; Jason Bruggemann; Vanessa Cropley; Vaidy Swaminathan; Suresh Sundram; Rhoshel Lenroot; Avril M Pereira; Andrew Zalesky; Chad Bousman; Christos Pantelis; Thomas W Weickert; Cynthia Shannon Weickert
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2021-03-24       Impact factor: 5.270

6.  Quality of life is associated with chronic inflammation in schizophrenia: a cross-sectional study.

Authors:  M Faugere; J A Micoulaud-Franchi; M Alessandrini; R Richieri; C Faget-Agius; P Auquier; C Lançon; L Boyer
Journal:  Sci Rep       Date:  2015-06-04       Impact factor: 4.379

Review 7.  Protein-C Reactive as Biomarker Predictor of Schizophrenia Phases of Illness? A Systematic Review.

Authors:  Laura Orsolini; Fabiola Sarchione; Federica Vellante; Michele Fornaro; Ilaria Matarazzo; Giovanni Martinotti; Alessandro Valchera; Marco Di Nicola; Alessandro Carano; Massimo Di Giannantonio; Giampaolo Perna; Luigi Olivieri; Domenico De Berardis
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

Review 8.  Longitudinal association between CRP levels and risk of psychosis: a meta-analysis of population-based cohort studies.

Authors:  Emanuele F Osimo; Luke Baxter; Jan Stochl; Benjamin I Perry; Stephen A Metcalf; Setor K Kunutsor; Jari A Laukkanen; Marie Kim Wium-Andersen; Peter B Jones; Golam M Khandaker
Journal:  NPJ Schizophr       Date:  2021-05-28

9.  Prevalence and correlates of low-grade systemic inflammation in adult psychiatric inpatients: An electronic health record-based study.

Authors:  Emanuele F Osimo; Rudolf N Cardinal; Peter B Jones; Golam M Khandaker
Journal:  Psychoneuroendocrinology       Date:  2018-03-01       Impact factor: 4.905

10.  Cardiometabolic risk in young adults with depression and evidence of inflammation: A birth cohort study.

Authors:  Benjamin I Perry; Bianca P Oltean; Peter B Jones; Golam M Khandaker
Journal:  Psychoneuroendocrinology       Date:  2020-04-18       Impact factor: 4.905

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.